Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Simplification of Imipenem Dosing by Removal of Weight-Based Adjustments.

Lala M, Brown M, Kantesaria B, Walker B, Paschke A, Rizk ML.

J Clin Pharmacol. 2018 Dec 11. doi: 10.1002/jcph.1356. [Epub ahead of print]

PMID:
30536420
2.

Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection.

Kakara M, Larson K, Feng HP, Shiomi M, Yoshitsugu H, Rizk ML.

J Infect Chemother. 2018 Dec 4. pii: S1341-321X(18)30457-4. doi: 10.1016/j.jiac.2018.11.005. [Epub ahead of print]

3.

Erratum for Rhee et al., "Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants".

Rhee EG, Rizk ML, Calder N, Nefliu M, Warrington SJ, Schwartz MS, Mangin E, Boundy K, Bhagunde P, Colon-Gonzalez F, Jumes P, Liu Y, Butterton JR.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e02197-18. doi: 10.1128/AAC.02197-18. Print 2018 Dec. No abstract available.

4.

Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection.

Bradley JS, Ang JY, Arrieta AC, Larson KB, Rizk ML, Caro L, Yang S, Yu B, Johnson MG, Rhee EG.

Pediatr Infect Dis J. 2018 Nov;37(11):1130-1136. doi: 10.1097/INF.0000000000002170.

PMID:
30153232
5.

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants.

Rhee EG, Rizk ML, Calder N, Nefliu M, Warrington SJ, Schwartz MS, Mangin E, Boundy K, Bhagunde P, Colon-Gonzalez F, Jumes P, Liu Y, Butterton JR.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00280-18. doi: 10.1128/AAC.00280-18. Print 2018 Sep. Erratum in: Antimicrob Agents Chemother. 2018 Nov 26;62(12):.

6.

Perspective on the State of Pharmacometrics and Systems Pharmacology Integration.

Trame MN, Riggs M, Biliouris K, Marathe D, Mettetal J, Post TM, Rizk ML, Visser SAG, Musante CJ.

CPT Pharmacometrics Syst Pharmacol. 2018 Oct;7(10):617-620. doi: 10.1002/psp4.12313. Epub 2018 Aug 21.

7.

Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model.

Wu J, Racine F, Wismer MK, Young K, Carr DM, Xiao JC, Katwaru R, Si Q, Harradine P, Motyl M, Bhagunde PR, Rizk ML.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02323-17. doi: 10.1128/AAC.02323-17. Print 2018 May.

8.

Validation of a Model Predicting Anti-infective Lung Penetration in the Epithelial Lining Fluid of Humans.

Aulin LBS, Valitalo PA, Rizk ML, Visser SAG, Rao G, van der Graaf PH, van Hasselt JGC.

Pharm Res. 2018 Jan 8;35(2):26. doi: 10.1007/s11095-017-2336-7. No abstract available.

9.

Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects.

Rizk ML, Rhee EG, Jumes PA, Gotfried MH, Zhao T, Mangin E, Bi S, Chavez-Eng CM, Zhang Z, Butterton JR.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01411-17. doi: 10.1128/AAC.01411-17. Print 2018 Mar.

10.

Single- and Multiple-Dose Pharmacokinetics of Once-Daily Formulations of Raltegravir.

Krishna R, Rizk ML, Larson P, Schulz V, Kesisoglou F, Pop R.

Clin Pharmacol Drug Dev. 2018 Feb;7(2):196-206. doi: 10.1002/cpdd.358. Epub 2017 Apr 17.

PMID:
28419778
11.

Erratum to: A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.

Anderson MS, Khalilieh S, Yee KL, Liu R, Fan L, Rizk ML, Shah V, Hussaini A, Song I, Ross LL, Butterton JR.

Clin Pharmacokinet. 2017 Jun;56(6):679-681. doi: 10.1007/s40262-017-0517-5. No abstract available.

PMID:
28185217
12.

Importance of Drug Pharmacokinetics at the Site of Action.

Rizk ML, Zou L, Savic RM, Dooley KE.

Clin Transl Sci. 2017 May;10(3):133-142. doi: 10.1111/cts.12448. Epub 2017 Feb 3. Review. No abstract available.

13.

Novel Gastroretentive Controlled Release Formulations for Once-Daily Administration: Assessment of Clinical Feasibility and Formulation Concept for Raltegravir.

Krishna R, Rizk ML, Larson PJ, Schulz V, Friedman E, Gupta P, Kesisoglou F, Connor A, McDermott J, Smith R, Evans P.

Ther Innov Regul Sci. 2016 Nov;50(6):777-790. doi: 10.1177/2168479016657130. Epub 2016 Jul 19.

PMID:
30231748
14.

A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.

Anderson MS, Khalilieh S, Yee KL, Liu R, Fan L, Rizk ML, Shah V, Hussaini A, Song I, Ross LL, Butterton JR.

Clin Pharmacokinet. 2017 Jun;56(6):661-669. doi: 10.1007/s40262-016-0458-4. Erratum in: Clin Pharmacokinet. 2017 Jun;56(6):679-681.

PMID:
27699622
15.

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.

Lucasti C, Vasile L, Sandesc D, Venskutonis D, McLeroth P, Lala M, Rizk ML, Brown ML, Losada MC, Pedley A, Kartsonis NA, Paschke A.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6234-43. doi: 10.1128/AAC.00633-16. Print 2016 Oct.

16.

Characterizing Class-Specific Exposure-Viral Load Suppression Response of HIV Antiretrovirals Using A Model-Based Meta-Analysis.

Xu Y, Li YF, Zhang D, Dockendorf M, Tetteh E, Rizk ML, Grobler JA, Lai MT, Gobburu J, Ankrom W.

Clin Transl Sci. 2016 Aug;9(4):192-200. doi: 10.1111/cts.12395. Epub 2016 May 12.

17.

Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid.

van Hasselt JG, Rizk ML, Lala M, Chavez-Eng C, Visser SA, Kerbusch T, Danhof M, Rao G, van der Graaf PH.

Br J Clin Pharmacol. 2016 Jun;81(6):1113-23. doi: 10.1111/bcp.12901. Epub 2016 Apr 1.

18.

Structure-Based Prediction of Anti-infective Drug Concentrations in the Human Lung Epithelial Lining Fluid.

Välitalo PA, Griffioen K, Rizk ML, Visser SA, Danhof M, Rao G, van der Graaf PH, van Hasselt JG.

Pharm Res. 2016 Apr;33(4):856-67. doi: 10.1007/s11095-015-1832-x. Epub 2015 Dec 1.

PMID:
26626793
19.

Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.

Nachman S, Alvero C, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Rizk ML, Spector SA, Frenkel LM, Worrell C, Handelsman E, Wiznia A.

J Pediatric Infect Dis Soc. 2015 Dec;4(4):e76-83. doi: 10.1093/jpids/piu146. Epub 2015 Feb 7.

20.

Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age.

Rizk ML, Du L, Bennetto-Hood C, Wenning L, Teppler H, Homony B, Graham B, Fry C, Nachman S, Wiznia A, Worrell C, Smith B, Acosta EP.

J Clin Pharmacol. 2015 Jul;55(7):748-56. doi: 10.1002/jcph.493. Epub 2015 Apr 13.

21.

Raltegravir pharmacokinetics in neonates following maternal dosing.

Clarke DF, Acosta EP, Rizk ML, Bryson YJ, Spector SA, Mofenson LM, Handelsman E, Teppler H, Welebob C, Persaud D, Cababasay MP, Wang J, Mirochnick M; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1097 Study Team.

J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):310-5. doi: 10.1097/QAI.0000000000000316.

22.

A pharmacokinetic comparison of adult and paediatric formulations of raltegravir in healthy adults.

Rhee EG, Rizk ML, Brainard DM, Gendrano IN 3rd, Jin B, Wenning LA, Wagner JA, Iwamoto M.

Antivir Ther. 2014;19(6):619-24. doi: 10.3851/IMP2765. Epub 2014 Mar 7.

PMID:
24608069
23.

Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.

Rizk ML, Houle R, Chan GH, Hafey M, Rhee EG, Chu X.

Antimicrob Agents Chemother. 2014;58(3):1294-301. doi: 10.1128/AAC.02049-13. Epub 2013 Dec 2.

24.

Ultrasensitive liquid chromatography-tandem mass spectrometric methodologies for quantification of five HIV-1 integrase inhibitors in plasma for a microdose clinical trial.

Sun L, Li H, Willson K, Breidinger S, Rizk ML, Wenning L, Woolf EJ.

Anal Chem. 2012 Oct 16;84(20):8614-21. doi: 10.1021/ac301581h. Epub 2012 Oct 2.

PMID:
23030780
25.

Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients.

Rizk ML, Hang Y, Luo WL, Su J, Zhao J, Campbell H, Nguyen BY, Sklar P, Eron JJ Jr, Wenning L.

Antimicrob Agents Chemother. 2012 Jun;56(6):3101-6. doi: 10.1128/AAC.06417-11. Epub 2012 Mar 19.

26.

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.

Eron JJ Jr, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, Young B, Katlama C, Gatell-Artigas JM, Arribas JR, Nelson M, Campbell H, Zhao J, Rodgers AJ, Rizk ML, Wenning L, Miller MD, Hazuda D, DiNubile MJ, Leavitt R, Isaacs R, Robertson MN, Sklar P, Nguyen BY; QDMRK Investigators.

Lancet Infect Dis. 2011 Dec;11(12):907-15. doi: 10.1016/S1473-3099(11)70196-7. Epub 2011 Sep 18. Erratum in: Lancet Infect Dis. 2011 Dec;11(12):895. Dosage error in article text.

PMID:
21933752
27.

Redox homeostasis phenotypes in RubisCO-deficient Rhodobacter sphaeroides via ensemble modeling.

Rizk ML, Laguna R, Smith KM, Tabita FR, Liao JC.

Biotechnol Prog. 2011 Jan-Feb;27(1):15-22. doi: 10.1002/btpr.506. Epub 2010 Oct 11.

PMID:
20939096
28.

Ensemble modeling of hepatic fatty acid metabolism with a synthetic glyoxylate shunt.

Dean JT, Rizk ML, Tan Y, Dipple KM, Liao JC.

Biophys J. 2010 Apr 21;98(8):1385-95. doi: 10.1016/j.bpj.2009.12.4308.

29.

Ensemble modeling for aromatic production in Escherichia coli.

Rizk ML, Liao JC.

PLoS One. 2009 Sep 4;4(9):e6903. doi: 10.1371/journal.pone.0006903.

30.

Ensemble modeling for strain development of L-lysine-producing Escherichia coli.

Contador CA, Rizk ML, Asenjo JA, Liao JC.

Metab Eng. 2009 Jul-Sep;11(4-5):221-33. doi: 10.1016/j.ymben.2009.04.002. Epub 2009 Apr 18.

PMID:
19379820
31.

Ensemble modeling of metabolic networks.

Tran LM, Rizk ML, Liao JC.

Biophys J. 2008 Dec 15;95(12):5606-17. doi: 10.1529/biophysj.108.135442. Epub 2008 Sep 26.

Supplemental Content

Support Center